[1]
|
Prescribing Information, Package Insert, “Qutenza? (Capsaicin) 8% Patch”, Initial US Approval: 2009
|
[2]
|
M. M. Backonja, “High-Concentration Capsaicin for the Treatment of Post-Herpetic Neuralgia and Other Types of Peripheral Neuropathic Pain,” European Journal of Pain Supplements, Vol. 4, No. 2, 2010, pp. 170-174.
doi:10.1016/S1754-3207(10)70529-0
|
[3]
|
M. M. Backonja, G. A. Irving, L. R. Webster and J. K. Tobias, “Tolerability of Qutenza (NGX-4010), an 8% Capsaicin Patch, for Postherpetic Neuralgia, (A299),” 2010. http:/asaabstracts.com
|
[4]
|
C. M. Campbell, R. R. Edwards, C. Carmona, M. Uhart, G. Wand, A. Carteret, Y. K. Kim, J. Frost and J. N. Campbell, “Polymorphisms in the GTP Cyclohydrolase Gene (GCH1) Are Associated With Ratings of Capsaicin Pain,” Pain, Vol. 141, No. 1-2, 2009, pp. 114-118.
doi:10.1016/j.pain.2008.10.023
|
[5]
|
P. Anand, “Peripheral and Central Mechanisms of Visceral Sensitization in Man,” Neurogastroenterology Motility, Vol. 19, No. 1, 2007, pp. 29-46.
doi:10.1111/j.1365-2982.2006.00873.x
|
[6]
|
R. Gerwin, “Myofascial and Visceral Pain Syndromes: Visceral-Somatic Pain Representations,” Clinical Neurobiology of Fibromyalgia and Myofascial Pain, Hayworth Press Inc, 2002, pp. 165-175.
|
[7]
|
C. H. M. Rains, “Topical Capsaicin. A Review of Its Pharmacological Properties and Therapeutic Potential In Post-herpetic Neuralgia, Diabetic Neuropathy and Osteoarthritis,” Drugs Aging, Vol. 7, No. 4, 1995, pp. 317328.
|